![Milind Deshpande](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 258 815 $ in data 31/05/2026
Milind S.
Deshpande was the founder of Hyku Biosciences, Inc., founded in 2021, where the titles held included President, Chief Executive Officer & Director from 2021 to 2024.
Current jobs include President & Chief Executive Officer at Achillion Pharmaceuticals, Inc. starting in 2024; Chairman at Avilar Therapeutics, Inc. since 2021; Director at Clear Creek Bio, Inc. since 2020; Independent Director at Spero Therapeutics, Inc. since 2023; and Venture Partner at RA Capital Management LP (Private Equity) since 2018.
Former jobs include Chief Executive Officer & Director at Achillion Pharmaceuticals, Inc. in 2018; Chief Executive Officer & Director at TRIANA Biomedicines, Inc. from 2019 to 2024; President, Chief Executive Officer & Director at Nayan Therapeutics, Inc. from 2019 to 2022; Associate Director-Lead Discovery at Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 2001; and Faculty Member at Boston University School of Medicine from 1988 to 1991.
Education includes a doctorate from The Ohio University conferred in 1986.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 23/06/2026 | 91.454 ( 0,16% ) | 258 815 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/08/2023 |
| ACHILLION PHARMACEUTICALS, INC. | Amministratore Delegato | 01/06/2024 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Investitore di Private Equity | 01/10/2018 |
Clear Creek Bio, Inc.
 Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for nucleotide synthesis | Direttore/Membro del Consiglio | 01/09/2020 |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops covalent drugs to treat cancer and other autoimmune diseases | Presidente | 01/01/2020 |
| Società | Posizione | Fine |
|---|---|---|
Santi Therapeutics, Inc.
 Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics to treat diseases | Amministratore Delegato | 01/03/2024 |
Nayan Therapeutics, Inc.
 Nayan Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Amministratore Delegato | 01/02/2022 |
| ACHILLION PHARMACEUTICALS, INC. | Amministratore Delegato | 02/05/2018 |
Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01/01/2001 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
The Ohio University
 The Ohio University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
Spero Therapeutics, Inc.
 Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
Boston University School of Medicine
 Boston University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clear Creek Bio, Inc.
Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for nucleotide synthesis | Health Technology |
Nayan Therapeutics, Inc.
Nayan Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Santi Therapeutics, Inc.
Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics to treat diseases | Health Technology |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops covalent drugs to treat cancer and other autoimmune diseases | Commercial Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
